Table 3.

Change in efficacy 2 weeks, 12 weeks and 24 weeks after the introduction of JAK inhibitors

	TOFA (n=153)†			BARI (n=141)†
	Change from baseline			Change from baseline
	Week 2	Week 12	Week 24	Week 2	Week 12	Week 24
CDAI	−12.3 (11.2)*	−17.2 (12.6)*	−18.1 (13.0)*	−11.5 (11.6)*	−18.3 (13.0)*	−19.3 (14.1)*
SDAI	−12.5 (11.6)*	−17.9 (13.5)*	−19.0 (14.1)*	−12.3 (12.5)*	−19.1 (13.8)*	−20.4 (15.0)*
HAQ-DI	−0.22 (0.41)*	−0.41 (0.53)*	−0.45 (0.61)*	−0.15 (0.38)*	−0.31 (0.55)*	−0.39 (0.65)*
CRP, mg/dL	−0.06 (-0.92–0.00)*	−0.05 (–1.30–0.02)*	−0.11 (–1.30–0.00)*	−0.07 (–0.70–0.00)*	−0.05 (–1.11–0.00)*	−0.13 (–1.55–0.02)*
ESR, mm/hour	−5.46 (14.21)*	−7.66 (21.9)*	−10.78 (26.7)*	−6.48 (14.66)*	−10.23 (22.77)*	−12.84 (33.39)*

Change from baseline data is mean (SD) and median (IQR).

*P≤0.001 from within-group mean change from baseline.

†The number of subjects changed after IPTW in the calculation; however, the actual number of subjects did not change.

BARI, baricitinib; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; JAK, Janus kinase; SDAI, Simplified Disease Activity Index; TOFA, tofacitinib.